NASDAQ:PBM Psyence Biomedical (PBM) Stock Price, News & Analysis $2.62 +0.04 (+1.55%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Psyence Biomedical Stock (NASDAQ:PBM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Psyence Biomedical alerts:Sign Up Key Stats Today's Range$2.50▼$2.7050-Day Range$2.36▼$11.5052-Week Range$2.36▼$138.78Volume26,650 shsAverage Volume656,565 shsMarket Capitalization$4.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. Read More Psyence Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScorePBM MarketRank™: Psyence Biomedical scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Psyence Biomedical. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPsyence Biomedical has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.29% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently increased by 1,219.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPsyence Biomedical does not currently pay a dividend.Dividend GrowthPsyence Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.29% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently increased by 1,219.67%, indicating that investor sentiment is decreasing significantly. News and Social Media1.0 / 5News Sentiment-0.25 News SentimentPsyence Biomedical has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Psyence Biomedical this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Psyence Biomedical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Psyence Biomedical is held by insiders.Percentage Held by Institutions77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Psyence Biomedical's insider trading history. Receive PBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psyence Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBM Stock News HeadlinesPsyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine ProductionSeptember 2 at 5:46 AM | finance.yahoo.comPsyence Biomedical (NASDAQ:PBM) Stock Price Down 5.4% - What's Next?August 30, 2025 | americanbankingnews.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. September 5 at 2:00 AM | Crypto 101 Media (Ad)Psyence Biomedical (NASDAQ:PBM) Trading Down 5.4% - Here's WhyAugust 30, 2025 | americanbankingnews.comPsyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025August 28, 2025 | globenewswire.comPsyence Biomedical Ltd. (PBM) Stock Price Today - WSJAugust 5, 2025 | wsj.comPsyence Biomedical stock soars after partner achieves ibogaine breakthroughAugust 1, 2025 | za.investing.comPsyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction BreakthroughAugust 1, 2025 | msn.comSee More Headlines PBM Stock Analysis - Frequently Asked Questions How have PBM shares performed this year? Psyence Biomedical's stock was trading at $16.8167 at the beginning of the year. Since then, PBM shares have decreased by 84.9% and is now trading at $2.54. How were Psyence Biomedical's earnings last quarter? Psyence Biomedical Ltd. (NASDAQ:PBM) issued its quarterly earnings results on Thursday, January, 23rd. The company reported $4.06 earnings per share (EPS) for the quarter. When did Psyence Biomedical's stock split? Psyence Biomedical's stock reverse split on the morning of Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Psyence Biomedical's major shareholders? Psyence Biomedical's top institutional shareholders include Parallel Advisors LLC (48.25%). How do I buy shares of Psyence Biomedical? Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Psyence Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ). Company Calendar Last Earnings1/23/2025Today9/05/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBM Previous SymbolNASDAQ:PBM CIK1985062 Webwww.psyencebiomed.com Phone510-214-3750FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.04 Quick Ratio11.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$1.74 per share Price / Cash Flow1.48 Book Value$11.83 per share Price / Book0.22Miscellaneous Outstanding Shares1,870,000Free Float1,800,000Market Cap$4.82 million OptionableN/A Beta0.18 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PBM) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.